Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Keith Villa, Ph.D., CERIA Brewing Co-founder and Brewmaster, and Creator of Blue Moon, Promotes Benefits of Non-Alcoholic Beer


“Mindful drinking among millennials – the ‘Sober Curious’ movement – and today’s more active lifestyles are also encouraging growth of the segment.”

At a time when the American public is more aware than ever of the importance of health and wellness, Keith Villa, Ph.D., the creator and former brewmaster of Blue Moon, and now co-founder of CERIA Brewing Company, makers of Grainwave and Indiewave non-alcoholic craft beers, is sharing his knowledge of the science behind non-alcoholic (NA) beer’s health benefits.

Dr. Villa, who is an expert in brewing science, speaks regularly on the science and art of brewing great tasting alcoholic and non-alcoholic beers. On Oct. 5, he presented an educational seminar at the 2020 National Beer Wholesalers Association (NBWA) virtual convention, the largest annual gathering of beer distributors in the country.

At the convention, Dr. Villa explained how numerous studies show plant-derived compounds such as hops and grains in beer contain important minerals and other compounds for improved health. According to numerous studies, these natural ingredients may promote cardiovascular health due to their polyphenol-rich nature, while the presence of essential oils known as “terpenes” are believed to help decrease inflammation, regulate blood pressure, and reduce stress and anxiety.

Moreover, NA beer specifically is a great “go to” beverage before and after exercise for rehydration and recovery due to its natural carbohydrates, sodium, and general fluid make-up, Dr. Villa said. That’s one reason today’s Olympians have been swept up in a new trend largely emerging from Bavaria: non-alcoholic athletic recovery beers. (https://www.npr.org/sections/thesalt/2018/02/24/588417922/olympians-are-using-non-alcoholic-beer-as-recovery-drinks-heres-the-science)

Dr. Villa is recognized as one of the world’s foremost authorities on Brewing Science and Fermentation Biochemistry, with a Ph.D. from the University of Brussels, and an undergraduate degree from University of Colorado in Molecular, Cellular, and Developmental Biology. During a 32-year career at MolsonCoors Brewing Company, he created many innovative beers, with the most famous being Blue Moon.

Health Benefits Drive the NA Market

Dr. Villa believes health and wellness is driving the 13% annual growth rate of the current $728 million U.S. NA beer market, according to Intercontinental Beverage Capital research.

Globally, the non-alcoholic beer market, currently at $17 billion, is projected to reach a market value of $25 billion by the end of 2024, according to Global Market Insights/Statista.     

“Mindful drinking among millennials – the ‘Sober Curious’ movement – and today’s more active lifestyles are also encouraging growth of the segment,” he says.

In 2011, the University of Munich investigated the effects of beer, which contains around 50 polyphenols, on athletes – whose intense physical activity can compromise their immune activity. In the study, when marathon runners were instructed to drink 1.5 liters of non-alcoholic beer per day, their risk of upper respiratory infection was significantly reduced. The activity of white blood cells, a good indicator of inflammation, was lowered 20 percent. (https://www.eurekalert.org/pub_releases/2011-06/tum-sds060811.php)

A 2012 German study printed in Medicine & Science in Sports & Exercise (January 2012) found that polyphenol-rich beverages such as NA beers may also prove to be effective in groups with chronic inflammation, such as the obese, and in the prevention of cancer, diabetes, and cardiovascular disease. (https://journals.lww.com/acsm-msse/Fulltext/2012/01000/Nonalcoholic_Beer_Reduces_Inflammation_and.4.aspx)

NA Beer has “No Limits”

In 2020, Dr. Villa’s CERIA Brewing Company introduced Grainwave NA, a refreshing, medium-bodied Belgian-Style White Ale, containing only 77 calories, which is brewed with blood orange peel and coriander. It is then dealcoholized to 0.00% alcohol by volume (ABV), which eliminates the alcohol. Most NA beers today fall under the TTB guidelines of <0.5% ABV which means they are not totally alcohol free, according to Dr. Villa.

CERIA Indiewave NA, at just 99 calories, is a flavorful West Coast IPA that perfectly balances Cascade, Citra, and Amarillo hops with light caramel malts for a smooth citrusy character, then is dealcoholized also to 0.00% ABV.

Both are about half the calories of comparable alcoholic brews.

CERIA has begun to launch its new “No Limits” marketing campaign which will be executed across digital advertising, social media, PR, and point-of-sale. According to Dr. Villa, “No Limits” refers to NA as the anytime, anywhere beverage – the ability to consume a great tasting NA beer anywhere an alcoholic beverage might affect performance, such as on the golf course, the ski slope, at business lunches, or while rock climbing – or even as a replacement for other NARTD (Non-Alcohol Ready To Drink) beverages.

For more information: http://www.na.ceriabrewing.com

Share article on social media or email:

The KIS Foundation, Inc. Hosts “Day of Giving” COVID-19/Crisis Care Package Giveaway for Sickle Cell Disease Community


These days, giving back is more important than ever and families living with or affected by Sickle Cell Disease will receive some extra needed assistance. The KIS Foundation, Inc. has partnered with BBVA and HERBALIFE Nutrition to supply families living with Sickle Cell Disease with COVID-19 care relief boxes, Crisis Care Packages, and new iPads to support virtual learning.

On Sunday, October 18, 2020, from 12 pm – 3 pm, The K.I.S Foundation, Inc. will host a drive-thru, no contact, COVID-19 Safety compliant distribution at 745 N. La Brea Ave, Inglewood, CA, 90302 for SCD families who register in advance via special invite. Families will receive a COVID-19 Care Relief Box containing essential healthcare items, a Crisis Care package filled with necessities SCD patients need during a health crisis (whether at home or in the hospital) PLUS a brand new iPad to aid in virtual learning due to the current pandemic.

“We are happy to assist vulnerable SCD patients and families during the pandemic as they stay healthy at-home, and encourage uninterrupted educational learning” says, KiKi Shepard, Founder of The KIS Foundation, Inc.

This giveaway is an opportunity to spread awareness about Sickle Cell Disease and will help students stay on track learning safely at-home with new iPads amply donated by our Technology sponsor HERBALIFE Nutrition.

“We’ve partnered with various organizations in the past to assist with their nutritional needs along with providing various educational tools. I am honored as a Herbalife Nutrition employee to assist the KIS Foundation, Inc. with their community educational outreach efforts,” says Diahanna Brown – Vice President, Worldwide & Corporate Events.

Generous sponsors supporting the CCPP/COVID-19 giveaway include BBVA, HERBALIFE Nutrition, James Pickens, Jr. Foundation, SermoonJoy Entertainment, Rocky Carroll, Charles F. Johnson, A New Day Foundation, and Adleane Hunter.

For media inquiries, contact Lisa Humphrey – Premier Concepts, email: media@premierconceptspr.com or call 310.293.4154.

About The KIS Foundation, Inc.

The KIS Foundation, Inc. is a non-profit 501(c) (3) organization, dedicated to improving the social health and quality of life for children, adults, and families living with Sickle Cell Disease. Founded by Ms. KiKi Shepard, who carries the SCD trait, she has advocated and raised awareness of Sickle Cell Disease over 19 years, because SICKNESS HAS NO BOUNDARIES AND COMPASSION HAS NO LIMITS.

To learn about future events and opportunities to volunteer or donate, please visit http://www.thekisfoundation.org.

About BBVA

BBVA USA Bancshares, Inc. is a Sunbelt-based bank holding company whose principal subsidiary, BBVA, operates 649 branches, including 336 in Texas, 89 in Alabama, 63 in Arizona, 61 in California, 45 in Florida, 37 in Colorado and 18 in New Mexico. BBVA ranks among the top 25 largest U.S. commercial banks based on deposit market share and ranks among the largest banks in Alabama (2nd), Texas (4th) and Arizona (6th).

About HERBALIFE Nutrition

Herbalife Nutrition is a global nutrition company. Since 1980, we have been on a mission to improve nutritional habits around the world with great-tasting, science-backed nutrition products that help people get the right balance of healthy nutrition.

Share article on social media or email:

Richard Lash MD Named New Chief Medical Officer of LUMEA


“I’m very excited to have joined such a forward thinking, innovative company as LUMEA, which is uniquely positioned to usher in the new age of digital pathology.” – Dr. Lash

Dr. Lash has extensive diagnostic experience in both academic and commercial environments, and has led the development of molecular diagnostics, clinical research, and biotechnology in several large organizations. Dr. Lash is taking on this role at LUMEA in addition to his current work as president of a medical consulting company in Texas and as Associate Clinical Professor of Pathology at UT-Southwestern Medical Center.

“We are pleased to have Dr. Lash join our company,” said John Wirthlin, Chief Executive Officer of LUMEA. “Dr. Lash is a nationally recognized pathologist who brings a wealth of medical and large-scale commercial laboratory experience to LUMEA. We are excited to work with Dr. Lash to establish our technology platform as the gold standard for digital pathology.”

Regarding his appointment, Dr. Lash said, “I’m very excited to have joined such a forward thinking, innovative company as LUMEA, which is uniquely positioned to usher in the new age of digital pathology by removing many of the obstacles that has stymied progress to date. LUMEA is driving cost saving measures while improving quality of both pre-analytic workflow and the diagnostic process itself.”

Previously, Dr. Lash was the CMO and EVP of Operations at Inform Diagnostics, formerly Caris Life Sciences, the largest independent anatomic pathology provider in the United States. He earned his medical degree from the University of Michigan and completed his residency in anatomic/clinical pathology at the Cleveland Clinic Foundation where he served as chief resident. He completed his fellowship in surgical pathology with subspecialty training in GI pathology. Dr. Lash has 84 research publications in major journals with over 1,300 citations and has written 6 book chapters. His research interests and experience will be an important driving factor in new product development and technology commercialization.

LUMEA is a leader in the commercialization of digital pathology technologies. Its proprietary system leverages biopsy handling technology, workflow improvements and the deployment of artificial intelligence in both pre-analytic and analytic phases of the diagnostic process. LUMEA’s technology results in measurably better quality and reduced time and cost throughout the diagnostic workflow. The company has commercialized the most advanced, fully integrated digital diagnostic platform on the market today, and its valued based business model is scaling nationally.

Share article on social media or email:

Ultrasound Industry Veterans Join EchoNous Senior Management


Their addition to the team signals our readiness to drive value and change in the global POCUS market.

EchoNous, leading developers of AI-driven products for the handheld point-of-care bedside ultrasound (POCUS) market, today announced the addition of three ultrasound industry veterans to its leadership team. Dave Willis has joined the company in the role of Chief Innovation & Strategy Officer, Graham Cox will serve as Senior Vice President, Commercial Operations, and Gillian Cox will join as VP of Marketing.

All three executives were key architects and builders of the first hand-carried point-of-care ultrasound product, SonoSite, and now join EchoNous to accelerate the global execution of POCUS 2.0 – defined by the company as the arrival of true diagnostic-grade, Ai-driven, hand-carried ultrasound tools. This new generation of POCUS is noteworthy for its applied use of deep learning and computer vision capabilities.

Willis brings more than 40 years of knowledge and experience to EchoNous, having formerly served at SonoSite as Executive of the company. A trained sonographer and graduate of the Wharton Business School executive program, he held leadership roles with ATL Ultrasound and Clarius – of which he was a cofounder – after departing SonoSite.

Graham Cox, who also brings four decades’ worth of experience to EchoNous, served at SonoSite alongside Willis; spending 13 years with the company, a stint that culminated in a role as Senior Global Distribution Executive. Following his tenure at SonoSite, he served as CEO of eZono AG, designers of tablet-based ultrasound systems.

“Both Dave and Graham were essential ingredients in building our previous company from a startup to a high-performing, high-value organization,” said Kevin Goodwin, CEO of EchoNous. “I am elated that they can join us again, now at EchoNous. Their addition to the team signals our readiness to drive value and change in the global POCUS market.”

Willis and Cox will be charged primarily with growing EchoNous’s newest offering, the KOSMOS platform. Approved by the FDA in March, KOSMOS offers AI-driven ultrasound in a hand-carried device. Focused on the abdomen and challenging areas to scan – notably, the heart and lungs – KOSMOS rises above the limitations of “quick look” handheld tools currently in the market, bringing diagnostic-grade imaging and functionality to bedside care.

EchoNous’s new VP of Marketing, Gillian Cox, was the cofounder of SonoSite Europe and then served as a global marketing executive at Sonosite before retiring. “I’m thrilled that Gill has opted to set aside her retirement to join our team and, once again, push the boundaries of ultrasound technology,” added Goodwin. “I couldn’t ask for a better marketing lead as we round out the next phase of our global execution.”

About EchoNous

Founded in 2016, EchoNous develops industry-leading, intelligent POCUS tools that help medical professionals solve common everyday problems in healthcare. Its flagship device, KOSMOS, offers diagnostic-quality heart, lung, and abdominal scans in a handheld tool. The product captures ultrasound, ECG, and digital stethoscope and offers AI-guided cardiac scanning – an industry first in a single device. Learn more at http://www.echonous.com.

Share article on social media or email:

Healthcare Companies Achieve Significant Savings with FraudScope’s New Provider Scope, an Online Provider Self-Monitoring Portal


FraudScope announces the launch of Provider Scope, a new solution for health plans that analyzes professional, facility, and pharmacy claims and coding practices to quickly identify outlier behavior, promote coding best practices, and reduce costs pre-claim.

Provider Scope’s artificial intelligence-driven technology empowers health plans with actionable insights about claims behavior so they can proactively engage providers to improve claims accuracy. Accessible through an interactive online portal, Provider Scope enables providers to self-monitor outlier behavior relative to their peers and to communicate with certified coders to learn about best practices. The results are generated using FraudScope’s patented AI platform that analyzes claims history and other data sources to understand behavioral norms and make it easy for providers to understand and visualize their outlier behavior.

“As healthcare costs continue to rise, our team continuously seeks new ways to empower health plans to monitor and contain costs,” stated Musheer Ahmed, CEO of FraudScope. “We developed Provider Scope to give health plans much-needed insights into the billing practices of their professional providers, facilities, and pharmacies. Provider Scope is a first-of-its-kind solution that helps healthcare companies and agencies improve claim accuracy while avoiding provider abrasion, bringing new levels of transparency to these groups.”

Instead of relying on broad coding guidelines sent out to their provider networks, health plans can now use Provider Scope to engage specific providers based on their actual claim patterns. Sharing the comparative coding practice data gives providers the information they need to bring their coding in line with best practices.

Unlike other provider education offerings that only analyze a small subset of simplistic codes and are limited in the information shared with providers, Provider Scope’s AI platform analyzes complex codes and shares additional information with providers to allow them to self-monitor and track their own progress. This is especially valuable for health plans that are inundated with numerous cases and would benefit from the automated nature of Provider Scope to manage outlier provider behavior, allowing their teams to focus on the most egregious cases. Through Provider Scope, plans can drive significantly larger savings with their existing staffing levels.

Provider Scope is available now with risk-free early adopter pricing and no-cost implementations for initial customers. To learn more or request a demo, visit us at https://www.FraudScope.com.

About FraudScope

FraudScope is a leading provider of artificial intelligence-driven applications that help healthcare companies and agencies control costs by identifying and investigating fraud, waste, abuse, and other anomalous cost drivers. The Fraud Scope, Insight Scope, and Provider Scope applications are built on our Forensic AI Platform, which analyzes existing claims data, detects practices that intentionally or unintentionally increase costs, and builds connections across the data to provide actionable insights. Our Software-as-a-Service applications are HIPAA-compliant and operate in a HITRUST-certified environment.

Share article on social media or email:

Weekly Campus-wide Testing Brings Early Success to Rose-Hulman in Navigating Pandemic


News Image

A Rose-Hulman Institute of Technology student wears a face shield and face mask–requirements for everyone within the campus community

“In our classrooms and throughout the Rose-Hulman community, we have come together in the shadow of this crisis to find new ways to not only sustain, but to strengthen the education we deliver,” – Rose-Hulman President Robert A. Coons

Behind a comprehensive return to campus plan – which included pre-return and ongoing COVID-19 surveillance testing of the entire campus population – Rose-Hulman Institute of Technology is successfully navigating the global pandemic, with students six weeks into the fall quarter.

During the fall quarter, all faculty, staff and students attending class/working on campus are required to participate in weekly surveillance testing.

With a student body of nearly 2,100 and more than 12,000 surveillance and pre-return tests conducted, the positivity rate to date has been well under 1 percent – hovering between 0.3 and 0.4 percent – compared to a roughly 5 percent national average. The undergraduate engineering college, which is annually ranked among the best STEM colleges in the nation, has required individuals on campus to wear face masks and practice social distancing and has employed an aggressive contact tracing and quarantine strategy to mitigate potential spread of the virus from positive individuals.

“I have a lot of friends who go to other universities. I’ll ask how it’s going, and most say not very well,” said Jonathan Kawauchi, a senior chemical engineering major and world news editor for the campus student newspaper, The Rose Thorn. Kawauchi wrote about the institute’s efforts for the paper’s first issue of the year.

“At Rose, I’ve been happy with how we’ve handled it so far,” he added. “I really appreciate the testing. That’s probably the biggest thing. Testing everyone who came in was so much more than what other universities are doing and I appreciate the numbers being released every week. I feel like Rose has been very up front about it and has been largely transparent. To me, that’s enough to feel safe coming here. I know friends going to other universities that are boycotting and protesting going to classes because the university is not being honest and is not taking those precautions. It feels like Rose is taking it seriously, which makes me feel safer for sure.”

The institute has made adjustments to its food service offerings, with more individually prepared meals and plexiglass dividers at dining tables to allow for better distancing and protection against airborne transmission. Additional enhanced cleaning protocols have also been established. Classrooms have been adjusted to allow for more distancing, with smaller laboratory class sizes where participants are required to wear both a mask and face shield. All faculty, staff and students received three Rose-Hulman branded face masks at the start of the 10-week fall academic quarter.

“In our classrooms and throughout the Rose-Hulman community, we have come together in the shadow of this crisis to find new ways to not only sustain, but to strengthen the education we deliver,” said Rose-Hulman President Robert A. Coons.

Faculty devised and implemented a new schedule of classes that relied heavily on hybrid courses where a portion of the course engagement occurs in a traditional face-to-face classroom and another portion is online.

“One lesson we learned from the past spring was the need to have classes that could quickly adapt to various delivery modes while meeting quality standards for accessibility, Learning Management System navigation and use, Universal Design for learning, and regular instructor-student and student-student interactions,” said Provost and Vice President for Academic Affairs Rick Stamper. “The Learning and Technology office worked this summer with a small team of faculty to develop and deliver a novel sequence of training and work sessions on developing high-quality courses and materials for use across a variety of delivery methods. The faculty did a wonderful job of preparing for the fall courses.”

While Kawauchi noted that student life has changed with fewer face-to-face experiences, students are being offered and are finding new and creative ways to connect and preserve as normal a college experience as possible. In addition to virtual club and organization meetings, they are able to engage in esports and intramural activities, like disc-golf, where they can safely distance while still socializing in person. Students have taken their responsibility to protect themselves and the greater community very seriously, said Dean of Students and Vice President for Student Affairs, Erik Hayes.

“When I talk to peers at other schools or students here with friends at other schools, some have had to shut down or go more online,” Hayes said. “Our students don’t want to do that. I do think more than most places, they’re doing everything they can to not be the reason this fails. I’m just so proud and impressed.”

With plans to move to a remote learning environment for the first three weeks of the winter quarter (Nov. 30-Dec. 22), hybrid learning for the rest of the winter, and in-person learning for the spring, Kawauchi is convinced students are committed to doing what it takes to see the year through.

“I hope no one slacks and I don’t think they will,” he said. “I think everyone takes it very seriously.”

About Rose-Hulman Institute of Technology

Founded in 1874, Rose-Hulman Institute of Technology is dedicated to preparing its students with the world’s best undergraduate science, engineering and mathematics education in an environment infused with innovation, intellectual rigor and individualized attention. The institute is consistently recognized nationally as an elite STEM school for distinctions that include faculty excellence, return on investment, value added and career services. Career placement is near 100 percent year after year. Six of the college’s professors are listed in the Princeton Review’s Best 300 Professors book. Located in Terre Haute, Indiana, Rose-Hulman has an enrollment of approximately 2,000 undergraduate students and nearly 100 graduate students. Learn more at http://www.rose-hulman.edu.

INTERVIEW AVAILABILITY

Rose-Hulman President Robert Coons is available for video conferencing or telephone interviews by appointment. Make arrangements through Dale Long, director of media relations, at dale.long@rose-hulman.edu or 812-877-8418.

Share article on social media or email:

Comply with the Latest Legal and Regulatory Developments Webinar Oct. 29, 2020


WCG FDAnews

WCG FDAnews

Want to get combination products to market faster? Considering premarket submissions like 510(k), De Novo or premarket approval (PMA)?

One must adhere to a wave of legal and regulatory developments from the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH). One must assess and comply with the drug patent and exclusivity provisions that now apply to drug-device combination products.

Three specialists from the FDA and Life Sciences practice of King & Spalding’s Washington, D.C. office are here help you do just that. Chris Markus, Esq. is a partner, Jessica Ringel, Esq. is counsel, and Quynh Hoang is a senior regulatory consultant.

They’ll provide tips for evaluating and addressing the new drug patent and exclusivity provisions. They will guide attendees on this new, potentially unfamiliar requirement by explaining the process and identifying resources, which can help ensure one is providing the appropriate responses and information to meet the new requirements and get products on the way to approval. Their updates will include:


  • Key resources for drug patent and exclusivity information, including the FDA’s Orange Book and other online CDER resources
  • Key considerations in confirming the duration of patents and exclusivity, such as additive pediatric exclusivity or patent term extensions
  • Timelines and milestones in the patent certification process, including certification to FDA, direct notifications to new drug applications (NDAs) and patent holders and their effect on clearance/approval timelines
  • Interactions with the drug patent holder when needed, including notifications and rights of reference
  • Information to include in the marketing submission to CDRH, such as Paragraph IV certification and confirmation of notifications

Knowledge is power and knowledge of the recent legal and regulatory developments impacting combination products means the power to comply and get them to market faster.

Interested in registering multiple sites?

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally

to learn about our special multisite discount.

Webinar Details:

Get Your Combination Products to Market Faster:

Comply with the Latest Legal and Regulatory Developments

An FDAnews Webinar

Thursday, Oct. 29, 2020, 1:30 p.m.-3:00 p.m. EDT

https://www.fdanews.com/combinationproductsfaster

Tuition:

$287 per site

Easy Ways to Register:

Online: https://www.fdanews.com/combinationproductsfaster

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations

Share article on social media or email:

MFB Fertility Announces Proov® Predict and Confirm, a New Dual Hormone Testing Kit for At-Home Use to Get the Full Ovulation Picture


Proov Predict and Confirm

We are so excited to launch Proov Predict and Confirm at-home testing kits to continue our mission of providing easy and affordable solutions for women to understand their personal reproductive health, especially during times like now, said MFB Fertility’s​ ​founder and CEO, Amy Beckley

Proov, a science-based hormone testing company, announces today the launch of Proov Predict and Confirm, an at-home dual hormone testing kit. Proov uses its resources and research to educate and empower women about their reproductive health for couples trying to conceive.

Proov Predict and Confirm tracks two key hormones for the full ovulation picture. Each kit includes fifteen Proov LH strips to predict ovulation, which lets women know the best time to “try.” The kit also includes five Proov PdG strips to confirm successful ovulation. By combining Proov LH and PdG tests in one dual hormone testing kit, women can both “predict” their fertile window and “confirm” successful ovulation, easily, accurately, and at home.

Proov is the first and only FDA-cleared PdG test to confirm ovulation at home, in which women can use the results to track and understand whether or not they are ovulating properly and use the information provided to have better conversations with their doctors. Their new combined 15 LH and five PdG strip Predict and Confirm kit allows for one full cycle’s worth of successful ovulation tracking and is available on proovtest.com and Amazon for $39.99.

“We are so excited to launch Proov Predict and Confirm at-home testing kits to continue our mission of providing easy and affordable solutions for women to understand their personal reproductive health, especially during times like now when in person treatment options can be limited, said MFB Fertility’s​ ​founder and CEO, Amy Beckley. At Proov, we want to help couples to build their families, with less need for costly treatments and less stress – which can be common when it comes to trying to conceive. With our new Predict and Confirm kit, women can get 99% accurate results and the full picture of their own ovulation cycles from the comfort of their own homes.”

To learn more about Proov®, visit proovtest.com, and to learn more about PdG and the benefits of tracking it, visit https://proovtest.com/pages/faq.

About MFB Fertility, Inc.

MFB Fertility, Inc. developed Proov®, an at-home PdG test that measures the presence of progesterone metabolite PdG in urine to help a woman confirm that she has ovulated successfully. Originally co-founded in Boulder, Colo. by two women who both struggled to conceive, MFB Fertility was created to empower women to know more about their menstrual cycles, ovulation health, and PdG levels. Don’t just predict ovulation, Proov it! For more information, please visit https://proovtest.com/.

Media Contact

Kristen Mondshein

kristen@kmmcommunications.com

Share article on social media or email:

Capsa Healthcare Announces the Kirby Lester KL-SR Pharmacy Robot Available On Federal Supplies Contract


Kirby Lester KL-SR Robot

The KL-SR has an industry-first cassette calibration system onboard

Capsa Healthcare announced today that its Kirby Lester KL-SR pharmacy robotic dispensing system is now available for purchase on the Capsa Federal Supplies Contract. The KL-SR also will be available for purchase on GSA Advantage.

The KL-SR secure robot is part of Capsa’s federal contract, V797P-2073D effective October 1, 2020.

The Kirby Lester KL-SR fully automates the labeling, counting, and presenting of complete prescriptions in busy outpatient and community pharmacies. The KL-SR has an industry-first cassette calibration system onboard – universal locking cassettes can handle any NDC, and never need recalibration. Locked cassettes and updated FillSafe security system protect the pharmacy’s inventory and guards against unauthorized access. The robot automates 108 medications – more than 50% of total daily orders, and includes biometrics for user tracking and reporting.

The KL-SR joins Capsa Healthcare’s KL1 and KL1Plus pharmacy counting devices on the existing FSS/GSA contract. The KL1 is a simple, accurate tablet/capsule counting device. The KL1Plus combines counting with scan-verification software to avoid prescription filling errors, and an electronic C-II log.

Please contact Capsa Healthcare for information about additional products on federal contract, in the areas of health IT, medication management, and pharmacy automation for acute care, extended care and a host of other settings.

About Capsa Healthcare

Capsa Healthcare is a worldwide leader in developing and delivering innovative healthcare solutions for a wide spectrum of care providers. With 50+ years of experience, Capsa Healthcare offers a unique ability to meet the demands of diverse healthcare environments and offers a broad range of products including medication carts, medical carts, point-of-care carts, and pharmacy automation solutions. Headquartered in Portland, OR, Capsa Healthcare has over 400 employees with management, sales, and production offices throughout the world. To learn more, visit http://www.capsahealthcare.com or call 800-437-6633.

Follow Capsa Healthcare on Facebook (https://www.facebook.com/capsahealthcare/), Twitter (https://twitter.com/CapsaHealthcare), and LinkedIn (https://www.linkedin.com/company/capsahealthcare).

Share article on social media or email:



Metcela’s VCAM-1 positive cardiac fibroblast to play key roles in heart function improvement in ischemic heart failure by promoting lymphangiogenesis


The non-clinical studies conducted by Metcela revealed at least two clear subpopulations of fibroblasts found in the human fetal heart: VCAM1-positive cardiac fibroblasts (VCFs) and VCAM1-negative cardiac fibroblasts (VNCFs). When examined with bioinformatics analyses, VCFs expressed numerous genes related to lymphatic vessel formation. Conversely, many of the genes expressed at higher levels in VNCFs were linked to fibrotic tissue formation. Lymphatic vascular formation assays showed significant stimulation of cardiac lymphatic cell network complexity, induced by VCFs compared to VNCFs. Recent studies have suggested that lymphangiogenesis improves cardiac function and repair by draining accumulated fluids and maintaining the physiological interstitial fluid equilibrium [1–3]. We hypothesized that VCFs may restore cardiac function in heart failure following myocardial infarction by enhancing lymphatic vessel formation.

Thus, to test whether lymphangiogenesis induced by VCFs can lead to improved mechanical properties and function of the heart, we performed in-vivo studies, in which human fetal heart-derived VCFs were injected into nude rat heart failure models with surgically induced myocardial infarction. The group that received VCF injection exhibited significant improvements in the cardiac function and restoration of the mechanical properties of ventricular walls by recruitment of lymphatic endothelial cells to the infarcts and subsequent lymphangiogenesis.

Further studies are underway to demonstrate the therapeutic effects of human adult heart-derived VCFs and identify the molecular signaling mechanisms that trigger lymphangiogenesis after treatment with VCFs.

This study was supported by grants from the New Energy and Industrial Technology Development Organization (NEDO).

■References

1.     Henri O, Pouehe C, Houssari M, Galas L, Nicol L, Edwards-Lévy F, et al. Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction. Circulation. 2016;133: 1484–1497. doi:10.1161/CIRCULATIONAHA.115.020143

2.     Shimizu Y, Polavarapu R, Eskla KL, Pantner Y, Nicholson CK, Ishii M, et al. Impact of lymphangiogenesis on cardiac remodeling after ischemia and reperfusion injury. J Am Heart Assoc. 2018;7: 1–14. doi:10.1161/JAHA.118.009565

3.     Uezumi A, Fukada S, Yamamoto N, Takeda S, Tsuchida K. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol. 2010;12: 143–152. doi:10.1038/ncb2014

■About the article

Title: “Human cardiac fibroblasts expressing VCAM1 improve heart function in postinfarct heart failure rat models by stimulating lymphangiogenesis”

Authors: Takahiro Iwamiya, Bertrand-David Segard, Yuimi Matsuoka, Tomomi Imamura

URL: https://doi.org/10.1371/journal.pone.0237810

■About VCF

Metcela discovered VCAM-1-positive Cardiac Fibroblast (VCF), a specific type of fibroblast that re-establishes a favorable microenvironment for regeneration and cardiac contractile function restoration within the damaged heart tissues. VCFs can easily be cultured and are now known to induce lymphangiogenesis and stimulate proliferation of cardiomyocytes to regenerate the damaged tissues of the heart. Metcela’s intellectual property on VCFs is covered by several patents (JP6241893 and JP6618066). Metcela plans to initiate an investigator-initiated Phase I clinical trial for autologous VCF in early 2021.

Corporate Overview

Headquarter: Tsuruoka-shi, Yamagata

Research Center: Life Innovation Center: 3-25-22 Tonomachi; Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0821; Japan

Co-CEOs: Takahiro Iwamiya, Kenichi Nogami

Foundation: March 2016

Website: https://www.metcela.com/en/

Share article on social media or email: